Article Text

Download PDFPDF
Impact of sustained virological response to chronic hepatitic C antiviral therapy on new onset diabetes mellitus type 2 after controlling for metabolic syndrome
  1. Prashant Pandya1,2,
  2. Chaitanya Pant2,
  3. Ryan Taylor2,
  4. Olurinde Oni1
  1. 1Kansas City Veterans Affairs Medical Center, Kansas City, Missouri, USA
  2. 2Division of Gastroenterology, Hepatology and Motility, Department of Internal Medicine, Kansas University Medical Center, Kansas City, Kansas, USA
  1. Correspondence to Dr Prashant Pandya, Kansas City Veterans Affairs Medical Center, Kansas City, 4801 E Linwood Blvd, MO 64128, USA; ppandya{at}


The high cost associated with antiviral treatment for chronic hepatitis C virus (HCV) infection mandates further investigation in the context of preventing complications such as type 2 diabetes mellitus (DM2). We determined the cumulative incidence of DM2 in subjects with chronic HCV infection who received concomitant pegylated interferon (Peg-IFN) and ribavirin. We conducted a retrospective analysis of data obtained from Veterans Administrations Informatics and Computing Infrastructure (VINCI) to identify an adult cohort of patients without diabetes with chronic HCV infection who received Peg-IFN-based therapy between October 2001 and December 2011. Patients with history of HIV, hepatitis B infection, hepatocellular cancer (HCC), non-HCC cancers, and history of transplantation were excluded. Sustained virological response (SVR) was defined as negative HCV RNA 3 months after completion of therapy. Using Cox proportional hazards regression for multivariable analysis, we determined that patients who achieved SVR were at a significantly less risk of developing DM2. Adjusted survival rates showed that the responders' group was significantly less likely to develop DM2 over time (HR 0.60, CI 0.48 to 0.74, p<0.001). Peg-IFN-based therapy in chronic HCV patients that resulted in SVR significantly decreased the risk of developing DM2 and independently predicts the development of new onset disease after controlling for correlates of metabolic syndrome.

  • Diabetes Mellitus
  • Disease Progression
  • Hepatitis C
  • Fatty Liver

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Contributors All the authors contributed to the conception, design, writing and critical analysis of this manuscript. PP and OO contributed to the statistical analysis of the data.

  • Competing interests None declared.

  • Ethics approval Kansas City Veterans Administration Medical Center Institutional Review Board (IRB).

  • Provenance and peer review Not commissioned; externally peer reviewed.